research use only

Hypericin MAO inhibitor

Name: Hypericin
Brand: Selleck Chemicals
SKU: S3273
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S3273

Hypericin (Hyp, HY) is a naturally occurring substance found in the common St. John's Wort (Hypericum species) with antidepressive, antineoplastic and antiviral (human immunodeficiency and hepatitis C virus) activities. This compound has inhibitory effects on MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450).

Chemical Structure

Molecular Weight: 504.44

Jump to

Quality Control

Batch: Purity: 98.92%

98.92

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other MAO Inhibitors	Moclobemide (Ro 111163) J147 Sennoside A Paeonol Isatin Norharmane Amezinium (methylsulfate) Xanthoangelol Iproniazid Myristicin

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (198.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	504.44	Formula	C₃₀H₁₆O₈	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	548-04-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	MAO PKC dopamine-beta-hydroxylase Reverse transcriptase Telomerase P450
References	[1] https://pubmed.ncbi.nlm.nih.gov/15638760/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-13)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06470451	TERMINATED	CTCL/ Mycosis Fungoides; CTCL; Mycosis Fungoides; Cutaneous T Cell Lymphoma	Soligenix	2025-01-07	PHASE3
NCT05872854	COMPLETED	Cutaneous T Cell Lymphoma; Mycosis Fungoides	Ellen Kim, MD	2023-08-21	PHASE2
NCT05442190	COMPLETED	Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris	Soligenix	2022-12-14	PHASE2
NCT06218940	Not yet recruiting	NSCLC Stage IV	Newsoara Biopharma Co. Ltd.	2024-12-01	Phase 1
NCT06149247	COMPLETED	Cutaneous T-Cell Lymphoma/Mycosis Fungoides	Soligenix	2023-12-05	PHASE2
NCT06094777	Not yet recruiting	Advanced Solid Tumor	Shanghai YingLi Pharmaceutical Co. Ltd.	2023-11-10	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):